Response by Siontis et al to Letter Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States"

Circulation. 2019 Mar 19;139(12):1563-1564. doi: 10.1161/CIRCULATIONAHA.118.039290.

Konstantinos C Siontis¹, Xiaosong Zhang², Douglas E Schaubel³, Xiaoxi Yao^{4

5}, Peter A Noseworthy^{1

4}, Nilay D Shah^{4

5}, Rajiv Saran^{2

6}, Brahmajee K Nallamothu^{7

8}

¹ Department of Cardiovascular Medicine (K.C.S., P.A.N.), Mayo Clinic, Rochester, MN.
² Department of Internal Medicine (X.Z., R.S.), University of Michigan, Ann Arbor.
³ Department of Biostatistics, School of Public Health (D.E.S.), University of Michigan, Ann Arbor.
⁴ Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (X.Y., P.A.N., N.D.S.), Mayo Clinic, Rochester, MN.
⁵ Department of Health Sciences Research, Division of Health Care Policy and Research (X.Y., N.D.S.), Mayo Clinic, Rochester, MN.
⁶ Kidney Epidemiology and Cost Center, School of Public Health (R.S.), University of Michigan, Ann Arbor.
⁷ Institute for Healthcare Policy and Innovation (B.K.N.), University of Michigan, Ann Arbor.
⁸ Division of Cardiovascular Medicine, Department of Internal Medicine (B.K.N.), University of Michigan, Ann Arbor.

No abstract available

Publication types